Use of danazol in systemic lupus erythematosus (SLE) thrombocytopenia
| Author | No. | Design | Remission (%) | Dose | Duration | Comment |
|---|---|---|---|---|---|---|
| Marino76 | 3 | Series | 3 (100%) | 200–600 | Prolonged | Failed intravenous Ig, intravenous glucocorticoids and splenectomy |
| Agnello77 | 3 | RBPCT | 3 (100%) | 600 | 1 month | Mild SLE, 7 patients in trial, 3 with low platelets |
| West79 | 6 | Series | 6 (100%) | 800 | 1 year | All failed glucocorticoids, 4/6 failed splenectomy |
| Blanco78 | 4 | Series | 4 (100%) | 400–800 | 18–36 months | All failed glucocorticoids and at least one other drug |
| Cervera80 | 16 | Series† | 16 (100%) | 200‡ | 2–49 months | All failed glucocorticoids, 5 failed splenectomy |
| Arnal74 | 18 | Series | 9 (50%) | 400–600 | 28 months | All treated with glucocorticoids |
Dose is given as milligram per day.
†This was a consecutive series of patients with SLE with thrombocytopenia and bleeding.
‡200 mg/day initially, then increasing 200 mg each week until a response was noted.
RBPCT, randomised blinded placebo-controlled trial.